Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: Final results of the randomized controlled phase 3 TAKT study

Yoshikazu Nakaoka, Mitsuaki Isobe, Yoshiya Tanaka, Tomonori Ishii, Seido Ooka, Hiroaki Niiro, Naoto Tamura, Shogo Banno, Hajime Yoshifuji, Yasushi Sakata, Atsushi Kawakami, Tatsuya Atsumi, Shunsuke Furuta, Hitoshi Kohsaka, Katsuya Suzuki, Ryoki Hara, Yasuhiro Maejima, Hiroshi Tsukamoto, Yoshinari Takasaki, Katsuhisa YamashitaNorihiro Okada, Shinji Yamakido, Syuji Takei, Shumpei Yokota, Norihiro Nishimoto

Research output: Contribution to journalArticlepeer-review

66 Citations (Scopus)


To investigate the long-term efficacy and safety of the IL-6 receptor antibody tocilizumab in patients with Takayasu arteritis (TAK). Methods: Patients completing the randomized, double-blind, placebo-controlled period of the TAKT (Takayasu arteritis Treated with Tocilizumab) trial were followed up during open-label extended treatment with weekly s.c. tocilizumab 162 mg for up to 96 weeks or longer, with oral glucocorticoid tapering performed at the investigators' discretion. Endpoints of the extension analysis included steroid-sparing effects of tocilizumab, imaging data, patient-reported outcomes (36-Item Short Form Health Survey) and safety. Results: All 36 patients enrolled in the double-blind period entered the open-label extension; 28 patients received tocilizumab for 96 weeks. The median glucocorticoid dose was 0.223 mg/kg/day at the time of relapse before study entry, 0.131 mg/kg/day (interquartile range 0.099, 0.207) after 48 weeks and 0.105 mg/kg/day (interquartile range 0.039, 0.153) after 96 weeks. Overall, 46.4% of patients reduced their dose to <0.1 mg/kg/day, which was less than half the dose administered at relapse before study entry (mean difference -0.120 mg/kg/day; 95% CI -0.154, -0.087). Imaging evaluations indicated that most patients' disease was improved (17.9%) or stable (67.9%) after 96 weeks compared with baseline. Mean 36-Item Short Form Health Survey physical and mental component summary scores and 7 of 8 domain scores were clinically improved from baseline and maintained over 96 weeks of tocilizumab treatment. No unexpected safety issues were reported. Conclusion: These results in patients with Takayasu arteritis provide evidence of a steroid-sparing effect and improvements in well-being during long-term treatment with once-weekly tocilizumab 162 mg, with no new safety concerns. Trial registration: JAPIC Clinical Trials Information, http://www.clinicaltrials.jp/user/cteSearch_e.jsp, JapicCTI-142616.

Original languageEnglish
Pages (from-to)2427-2434
Number of pages8
JournalRheumatology (United Kingdom)
Issue number9
Publication statusPublished - 2020 Sept 1


  • Takayasu arteritis
  • biological therapies
  • immunosuppressants
  • quality of life
  • vasculitis

ASJC Scopus subject areas

  • Rheumatology
  • Pharmacology (medical)


Dive into the research topics of 'Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: Final results of the randomized controlled phase 3 TAKT study'. Together they form a unique fingerprint.

Cite this